These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 3051946)

  • 1. [Citrate (CG-120) therapy in urolithiasis. 2. Effect on urinary and serum biochemistry ].
    Ohkawa T; Ebisuno S; Morimoto S; Yasukawa S; Sonoda T; Koide T; Oka T; Aso Y; Higashihara E; Kitagawa R
    Hinyokika Kiyo; 1988 May; 34(5):918-31. PubMed ID: 3051946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Citrate (CG-120) therapy for urolithiasis. 1. Clinical effects].
    Ohkawa T; Ebisuno S; Morimoto S; Yasukawa S; Sonoda T; Koide T; Oka T; Aso Y; Higashihara E; Kitagawa R
    Hinyokika Kiyo; 1988 May; 34(5):905-17. PubMed ID: 3051945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of potassium and magnesium supplementations on urinary risk factors of renal stone patients.
    Jaipakdee S; Prasongwatana V; Premgamone A; Reungjui S; Tosukhowong P; Tungsanga K; Suwantrai S; Noppawinyoowong C; Maskasame S; Sriboonlue P
    J Med Assoc Thai; 2004 Mar; 87(3):255-63. PubMed ID: 15117041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Body size and 24-hour urine composition.
    Taylor EN; Curhan GC
    Am J Kidney Dis; 2006 Dec; 48(6):905-15. PubMed ID: 17162145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physiological and physiochemical correction and prevention of calcium stone formation by potassium citrate therapy.
    Pak CY; Sakhaee K; Fuller CJ
    Trans Assoc Am Physicians; 1983; 96():294-305. PubMed ID: 6679957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of urinary oxalate by combined calcium and citrate administration without increase in urinary calcium oxalate stone formers.
    Ito H; Suzuki F; Yamaguchi K; Nishikawa Y; Kotake T
    Clin Nephrol; 1992 Jan; 37(1):14-8. PubMed ID: 1541059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of renal stone risk by potassium-magnesium citrate during 5 weeks of bed rest.
    Zerwekh JE; Odvina CV; Wuermser LA; Pak CY
    J Urol; 2007 Jun; 177(6):2179-84. PubMed ID: 17509313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary response to oral potassium citrate therapy for urolithiasis in a private practice setting.
    Nicar MJ; Hsu MC; Fetner C
    Clin Ther; 1986; 8(2):219-25. PubMed ID: 3698069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in urinary stone risk factors in hypocitraturic calcium oxalate stone formers treated with dietary sodium supplementation.
    Stoller ML; Chi T; Eisner BH; Shami G; Gentle DL
    J Urol; 2009 Mar; 181(3):1140-4. PubMed ID: 19152919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Risk indicators of urinary calculus formation: value of oxalate and citrate excretion in comparison with the oxalate tolerance value].
    Hannak D; Burczyk U; Bartelt U; Kattermann R
    Urologe A; 1989 Jan; 28(1):20-4. PubMed ID: 2922896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physicochemical action of potassium-magnesium citrate in nephrolithiasis.
    Pak CY; Koenig K; Khan R; Haynes S; Padalino P
    J Bone Miner Res; 1992 Mar; 7(3):281-5. PubMed ID: 1585829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lemonade therapy increases urinary citrate and urine volumes in patients with recurrent calcium oxalate stone formation.
    Penniston KL; Steele TH; Nakada SY
    Urology; 2007 Nov; 70(5):856-60. PubMed ID: 17919696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin resistance and low urinary citrate excretion in calcium stone formers.
    Cupisti A; Meola M; D'Alessandro C; Bernabini G; Pasquali E; Carpi A; Barsotti G
    Biomed Pharmacother; 2007 Jan; 61(1):86-90. PubMed ID: 17184967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Exaggerated calciuric response to an acute acid load in patients forming renal calcium stones].
    Normand M; Cayotte JL; Houillier P; Peuchant A; Paillard M
    Nephrologie; 1993; 14(6):283-5. PubMed ID: 8145886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Oxalate stone prophylaxis by alkalinizing therapy (author's transl)].
    Butz M
    Urologe A; 1982 May; 21(3):142-6. PubMed ID: 7048691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term treatment of calcium nephrolithiasis with potassium citrate.
    Pak CY; Fuller C; Sakhaee K; Preminger GM; Britton F
    J Urol; 1985 Jul; 134(1):11-9. PubMed ID: 3892044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Calcium and citrate excretion by patients with calculi and healthy probands during induced acidosis].
    Bothor C; Berg W; Donner M; Pirlich W
    Urologe A; 1989 Mar; 28(2):112-5. PubMed ID: 2718293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of fasting hypercalciuria associated with increased citraturia in the ambulatory evaluation of nephrolithiasis.
    Damasio B; Massarino F; Durand F; Banchero R; Bottino P; De Franchis V; Carmignani G; Cannella G
    J Nephrol; 2005; 18(3):262-6. PubMed ID: 16013013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical studies of citrate therapy on urolithiasis--estimations of urinary citrate excretion in patients with urolithiasis and the results of treatment with sodium-potassium citrate].
    Yasukawa S
    Nihon Hinyokika Gakkai Zasshi; 1988 Apr; 79(4):620-8. PubMed ID: 3226014
    [No Abstract]   [Full Text] [Related]  

  • 20. Stone forming risk of calcium citrate supplementation in healthy postmenopausal women.
    Sakhaee K; Poindexter JR; Griffith CS; Pak CY
    J Urol; 2004 Sep; 172(3):958-61. PubMed ID: 15311008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.